The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics,
pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this
study. Part 1 is a dose escalation which will follow an accelerated titration design (ATD).
Part 2 is a dose expansion in the same relapsed/refractory (R/R) AML subtypes as in Part 1.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.